Cellceutix has brought together leading figures in the health and science arenas to work toward the goal of developing innovative small molecule therapies for areas of unmet medical need, particularly infectious disease, oncology and dermatology. The officers and advisors of Cellceutix include pioneers in the fields of cancer and genetics, as well as pharmaceutical executives. Their invaluable experiences cover all areas of researching, developing, and marketing ground breaking therapies.
Officers and Board of Directors
Leo Ehrlich, CPA - Chief Executive Officer and CFO, Board of Directors
Mr. Ehrlich is a co-founder of Cellceutix and has served as Chief Financial Officer (CFO) and Director since inception in June 2007 and as Chief Executive Officer (CEO) since November 2010. Mr. Ehrlich has over 25 years of executive leadership experience in building and managing emerging growth companies. Prior to Cellceutix, Mr. Ehrlich served as CFO and director of Nanoviricides, a publicly-traded company developing nanotechnology-based anti-viral medicines. Prior to that, Mr. Ehrlich held numerous executive positions, including CEO, President, CFO, and Director at StatSure Diagnostic Systems, Inc., a diagnostic company in the HIV space. Mr. Ehrlich is a Certified Public Accountant and received his BBA from Bernard Baruch College of the City University of New York.
Krishna Menon, RCM, PhD, VMD - President, Chief Scientific Officer, Board of Directors
Dr. Krishna Menon has more than 25 years of experience in drug development with academia and industry. Dr. Menon is a co-founder of Cellceutix and has served as President and Director since inception in June 2007. Prior to Cellceutix, Dr. Menon served at Eli Lilly as Group Leader, Cancer In Vivo Research and Clinical Development. At Lilly, Dr. Menon played a key role in lead selection and pre-clinical development of Gemzar and Alimta, two anti-cancer drugs which have generated billions of dollars in yearly revenue. In addition, Lilly honored Dr. Menon with the prestigious President’s Recognition Award. Prior to Eli Lilly, Dr. Menon operated his own veterinary oncology and drug development consultancy practice. Earlier in his career, he held research scientist positions at Miles Laboratories and Dana Farber Cancer Research Institute, where he worked under the direction of Dr. Emil Frei, one of the world’s leading oncologists and a leader in medical research. Dr. Menon is a trained veterinary surgeon and holds a PhD in Pharmacology from Kerala University. His PhD work focused on anti-folate therapy of various cancers.
James Alexander, MD, MPH, FACP – Chief Operating Officer
Dr. Alexander previously held clinical development and/or pharmacovigilance positions with SmithKline Beecham, Glaxo, Glaxo Wellcome, and BioCryst. He has contributed to clinical development programs supporting the approval of drugs for the treatment of bacterial and viral infections (HIV, herpes viruses, and influenza), asthma, COPD, and migraine. Dr. Alexander received his M.D. from the University of Mississippi and his M.P.H. from the University of Alabama at Birmingham. He is board certified in internal medicine and infectious diseases.
Daniel Jorgensen, MD, MPH, MBA, FAAP – Chief Medical Officer
Dr. Jorgensen is an accomplished physician executive with over 16 years of Industry experience, including 10 years at Pfizer. Previously, he was the Chief Medical Officer at PolyMedix, Inc., where he worked on brilacidin, the first in a new class of antibiotics known as defensin-mimetics, and thereafter, he continued his work as a consultant to Cellceutix, before joining Cellceutix as Chief Medical Officer. Dr.Jorgensen has a special interest in the development of single-dose and short-course antibiotics, particularly those that can reduce the burden of antimicrobial resistance. At Pfizer, he was the Global Clinical Leader for azithromycin and the Development Team Leader for dalbavancin. He began his Industry career at Pasteur Merieux Connaught, in the area of vaccine development. In these leadership roles, he has successfully ushered several products from early clinical development through full regulatory approval, both in the U.S. and abroad, playing a key role in NDA submissions and FDA Advisory Committee Meetings. Dr. Jorgensen is a CDC-trained epidemiologist (EIS Officer) and is the former Chief Medical Officer for the State of Montana. Dr. Jorgensen received his undergraduate degree from Yale, his MD from the University of Wisconsin, his MPH from the University of Washington, and his MBA from Yale. He is board-certified in pediatrics, infectious diseases, and preventive medicine.
Emil Frei III, MD - (In Memoriam)
Dr. Frei was known as one of the world’s leading oncologists, a pioneer of chemotherapy and a leader in medical research, clinical practice and education. His distinguished career included 40 years in top leadership positions such as Chief of Medicine at National Cancer Institute, Associate Scientific Director at M. D. Anderson, and Director and Physician-in-Chief at the Dana-Farber Cancer Institute.
Dr. Frei had unparalleled experience in the development of new cancer drugs. He is often referred to as the “Father of the Cure for Childhood Leukemia” because of his collaborative work with Dr. Emil J. Freireich.
Paul Marks, MD
As President and Chief Executive Officer, Dr. Marks led Memorial Sloan-Kettering Cancer Center for 19 years. He remains a vital part of MSKCC as President Emeritus and Member of the Sloan-Kettering Institute. Dr. Marks’s research in cell biology and cancer genetics has made major contributions toward a new approach to cancer treatment and prevention, through the development of new and more potent chemotherapy and chemoprevention agents. He also helped establish the highest standards for research and patient care at MSKCC and has provided leadership in the national and international medical science community.
Samuel Danishefsky, PhD, Scientific Advisor
Dr. Samuel Danishefsky is regarded as one of the world’s leading chemists in cancer research. He is an internationally recognized leader in chemistry, specializing in the synthesis of biologically active organic compounds. Dr. Danishefsky earned his Ph.D. in chemistry from Harvard. He spent 14 years at Yale University, where he rose to the rank of Sterling Professor of Chemistry, the highest academic rank at Yale University, awarded to a tenured faculty member considered one of the best in his or her field. By 1991, he was also sharing his time with Memorial Sloan-Kettering Cancer Center as director of the Laboratory for Cancer Research Bioorganic Chemistry, becoming chair in 1993. He accepted an appointment as professor at Columbia University in 1993, and now conducts research at both institutions.
Paul Ginsburg, PhD, Scientific Advisor
Dr. Ginsburg has authored the patent application covering the Cellceutix anticancer product Kevetrin which has been filed in the United States and other countries and has advised Cellceutix on patent and licensing matters during the past few years.
Dr. Ginsburg has spent most of his career in law firms and as corporate counsel representing large and small pharmaceutical, biotechnology, chemical and consumer product companies. He recently retired from Pfizer Inc., where he served as Head of the New York Patent Department and worked on patent matters relating to several blockbuster products, including Viagra and Chantix, and represented Pfizer on the intellectual property committees of the National Association of Manufacturers, the Chemical Manufacturers Association and the Biotechnology Industry Organization. Dr. Ginsburg has lectured widely on pharmaceutical and biotechnology patent prosecution and licensing at the Practicing Law Institute and Columbia Law School and before other groups. Prior to his twenty –year career at Pfizer, Dr. Ginsburg was a senior attorney at Schering-Plough. He was subsequently recruited by Merck and then by the highly respected IP firm Fish & Neave.
Dr. Ginsburg is perhaps most well-known as the author of the patent covering Schering- Plough’s hugely successful product Claritin. He also authored important patents covering Schering-Plough’s highly successful alpha-interferon product.
Dr. Ginsburg received his Ph.D. in Chemistry from the City University of New York and his law degree from Columbia University where he was a Harlan Fiske Stone Scholar. He was elected to Phi Beta Kappa at the City College of New York and to the scientific research honor society Sigma Xi at CUNY.
Jim Boeheim, Business Advisor
Coach Boeheim has earned icon status in the world of basketball. Coaching on the sidelines of the Carrier Dome court that is now named after him, Boeheim has a 962–326 (.747) overall record; ranking him second in wins among active Division I coaches and third all-time in college basketball. Syracuse has nine Big East regular season championships, five Big East Tournament championships and 28 trips into the NCAA Tournament, including four Final Four appearances with a NCAA championship in 2003. Boeheim has earned bronze and gold medals for his role as assistant coach in the 1990 FIBA World Championship, the 2006 FIBA World Championship, the 2008 Summer Olympics, the 2010 FIBA World Championships in Turkey, and the 2012 Summer Olympics. In September 2005, Boeheim was inducted into the Basketball Hall of Fame.
Boeheim’s list of basketball accolades are only paralleled by his philanthropic efforts in the field of cancer. Surviving his own battle with prostate cancer, Boeheim now heads the Jim and Juli Boeheim Foundation and has become a major advocate for Coaches vs. Cancer, the Children’s Miracle Network, the Make-A-Wish Foundation, Easter Seals, the Special Olympics and more. His dedication to Coaches vs. Cancer, a non-profit collaboration between the National Association of Basketball Coaches and the American Cancer Society, has helped raise $4.5 million for the American Cancer Society’s Central New York chapter over the past 12 years.